NAD+

Mechanism

NAD+ is a critical molecule found in every cell of your body that serves as fuel for hundreds of essential biological processes, including energy production, DNA repair, and cellular aging defenses. NAD+ levels naturally decline with age, and restoring them through supplementation or injection has been shown to improve energy, support healthy aging, and enhance cellular repair mechanisms. Injectable NAD+ delivers the molecule directly into the bloodstream, bypassing digestion for maximum availability.

Effects

## NAD+ — System-by-System Effects (Comprehensive Deep Dive) ### Cellular Energy & Mitochondrial Function (Primary) - **Electron transport chain**: NAD+ is an essential cofactor in complexes I and III of the mitochondrial electron transport chain. Declining NAD+ levels directly impair ATP production. Restoring NAD+ levels can increase cellular ATP output by 20-40% in aged tissues. [Tier 1 — well-established biochemistry] - **Mitochondrial biogenesis**: NAD+ activates SIRT1 and SIRT3, which upregulate PGC-1α, the master regulator of mitochondrial biogenesis. More NAD+ = more functional mitochondria. [Tier 1 — established molecular biology] - **Mitochondrial membrane potential**: Adequate NAD+ maintains proper mitochondrial membrane potential (ΔΨm), preventing premature apoptosis and improving cellular resilience. [Tier 1] - **TCA cycle function**: NAD+ is required for multiple steps of the citric acid cycle. Depletion creates a metabolic bottleneck that cascades into fatigue, brain fog, and tissue dysfunction. [Tier 1] ### Sirtuin Activation Pathway (The Central Mechanism) - **SIRT1 (nuclear)**: DNA repair, gene silencing, inflammation control, circadian rhythm regulation. SIRT1 is NAD+-dependent — it literally cannot function without adequate NAD+. This is why NAD+ is considered upstream of most longevity pathways. [Tier 1] - **SIRT3 (mitochondrial)**: Deacetylates mitochondrial proteins, reduces oxidative stress, improves fatty acid oxidation. SIRT3 knockout mice show accelerated aging. [Tier 1] - **SIRT6 (nuclear)**: Telomere maintenance, DNA double-strand break repair, glucose homeostasis. SIRT6 overexpression extends lifespan in mice. [Tier 1] - **The NAD+-Sirtuin-Longevity axis**: This is the core thesis — declining NAD+ with age → reduced sirtuin activity → accelerated aging across all systems. Restoring NAD+ should restore sirtuin function. [Tier 1 for mechanism, Tier 2 for clinical translation] ### DNA Repair & Genomic Stability - **PARP activation**: PARPs (poly-ADP-ribose polymerases) consume NAD+ to repair DNA damage. In aging, increased DNA damage means increased PARP activity, which depletes NAD+, creating a vicious cycle. Supplementing NAD+ breaks this cycle. [Tier 1 — established biochemistry] - **CD38 competition**: CD38 (an NAD+-consuming enzyme) increases with age and inflammation. CD38 is now considered the primary driver of age-related NAD+ decline — more so than reduced synthesis. [Tier 1 — Camacho-Pereira et al., 2016] - **Genomic instability**: NAD+ depletion impairs both base excision repair and double-strand break repair, accelerating mutation accumulation. [Tier 1] ### Neurological System - **Neuroprotection**: NAD+ supports neuronal energy metabolism, synaptic plasticity, and resistance to excitotoxicity. Patients commonly report improved mental clarity within 24-48 hours of IV NAD+. [Tier 2 for mechanism, Tier 3 for clinical observation] - **Neurodegenerative disease**: Preclinical evidence in Alzheimer, Parkinson, and ALS models shows NAD+ restoration slows neurodegeneration. Human translation is still early. [Tier 2] - **Addiction and withdrawal**: IV NAD+ has been used in addiction medicine clinics for 15+ years. The BR+NAD protocol (Brain Restoration Plus NAD) is used for alcohol, opioid, and stimulant detoxification. Patients report dramatically reduced withdrawal symptoms and cravings. [Tier 3 — clinical observation, no RCTs] - **Mood and cognition**: Many patients report antidepressant effects and improved cognitive function. Mechanism likely involves improved neuronal energy metabolism and neurotransmitter synthesis. [Tier 3] ### Cardiovascular System - **Cardiac energy metabolism**: The heart is the most metabolically active organ. NAD+ depletion impairs cardiac contractility. Restoring NAD+ improves cardiac function in preclinical heart failure models. [Tier 2] - **Vascular function**: NAD+/SIRT1 pathway maintains endothelial function, promotes vasodilation, and reduces vascular inflammation. [Tier 2] - **Blood pressure**: Some patients report modest blood pressure improvements with sustained NAD+ supplementation. [Tier 3] ### Metabolic System - **Insulin sensitivity**: NAD+/SIRT1 improves insulin signaling and glucose uptake. NMN supplementation improved insulin sensitivity in prediabetic women (Yoshino et al., 2021, Science). [Tier 1 — RCT data] - **Fatty acid oxidation**: SIRT3-mediated deacetylation of mitochondrial enzymes enhances fat burning. [Tier 1] - **Obesity and metabolic syndrome**: NAD+ precursors show benefit in animal models of obesity. Human data is emerging but promising. [Tier 2] ### Immune System - **Immune cell metabolism**: T cells, macrophages, and NK cells require NAD+ for activation and effector function. Age-related NAD+ decline contributes to immunosenescence. [Tier 2] - **Inflammatory regulation**: SIRT1 deacetylates NF-κB, reducing chronic inflammation (inflammaging). This is one of the most clinically relevant mechanisms. [Tier 1 for mechanism] - **Senescent cell response**: NAD+ may modulate the senescence-associated secretory phenotype (SASP), reducing the inflammatory output of senescent cells. [Tier 2] ### Musculoskeletal System - **Muscle function**: NAD+ depletion in aged muscle reduces contractile function and regenerative capacity. NMN restores muscle function in aged mice. [Tier 2] - **Sarcopenia**: NAD+ restoration may slow age-related muscle loss through improved mitochondrial function and stem cell activation. [Tier 2] - **Exercise capacity**: Some athletes and biohackers report improved exercise performance and recovery with NAD+ supplementation. [Tier 3] ### Reproductive/Hormonal System - **Ovarian aging**: NAD+ precursors (NMN) improved oocyte quality and fertility in aged mice (Bertoldo et al., 2020, Cell Reports). This generated significant interest in reproductive medicine. [Tier 2] - **Testicular function**: NAD+ supports Leydig cell function and testosterone production in preclinical models. [Tier 2] ### The Methylation Concern (Critical for Practitioners) - **Methyl group consumption**: NAD+ metabolism, particularly through the nicotinamide pathway, consumes methyl groups via NNMT (nicotinamide N-methyltransferase). High-dose NAD+ precursors can deplete SAMe (S-adenosylmethionine), the body's primary methyl donor. [Tier 2 — established biochemistry with clinical relevance] - **Clinical implications**: Patients with MTHFR polymorphisms or existing methylation issues may experience worsened symptoms (anxiety, insomnia, mood changes) with high-dose NAD+. [Tier 3 — clinical observation] - **Mitigation**: Co-supplement with methylfolate, methylcobalamin (B12), TMG (trimethylglycine/betaine), and/or SAMe when using high-dose NAD+ protocols. Many experienced practitioners now consider methyl support mandatory, not optional. [Tier 3 — practitioner consensus]

Practitioner Guide

## NAD+ — Practitioner Guide (Comprehensive) ### Clinical Profile NAD+ (nicotinamide adenine dinucleotide) is arguably the most important molecule in longevity medicine. It is an essential coenzyme in every living cell, required for >500 enzymatic reactions. NAD+ levels decline 50%+ between ages 40-60, and this decline is now considered a hallmark of aging. ### Routes of Administration — The Great Debate #### IV NAD+ (Intravenous) - **The gold standard for acute restoration**: Bypasses all absorption and metabolism concerns. Directly raises intracellular NAD+ levels. - **Typical protocols**: 250-750mg per infusion, dripped over 2-4 hours. Higher doses (1000-1500mg) used in addiction protocols. - **Loading protocol**: 4-6 infusions over 2 weeks (Mon/Wed/Fri or similar), then monthly maintenance. - **What patients actually experience**: The infusion itself is often uncomfortable — chest tightness, nausea, abdominal cramping, anxiety, flushing. These side effects are dose-rate dependent. Slow the drip = reduce side effects. Many clinics now use 4-6 hour infusions instead of 2-hour pushes. - **Post-infusion experience**: Most patients report a dramatic "clarity" and energy boost 2-12 hours after infusion. Many describe it as "someone turned the lights on." Sleep quality often improves dramatically on infusion nights. - **Peak effect**: Days 1-3 post-infusion. Some patients describe a "glow" that lasts 2-4 weeks. - **Cost**: $250-750 per infusion depending on dose and clinic. This is the major barrier. - **Clinical observation**: IV NAD+ produces the most consistent and dramatic subjective responses of any longevity intervention. Even skeptical patients often become believers after their first infusion. #### Subcutaneous NAD+ Injection - **Emerging alternative**: Self-administered SC injections of NAD+ solution (typically 50-200mg per injection). - **Advantages**: More affordable than IV, can be done at home, avoids the lengthy infusion time. - **Disadvantages**: Injection site burning/stinging is common. NAD+ is acidic and causes local irritation. Some patients cannot tolerate it. - **Typical protocol**: 100-200mg SC daily or every other day for loading, then 2-3x/week for maintenance. - **Practitioner tip**: Inject slowly, use a 27-30g needle, rotate sites, and some practitioners buffer the solution with sodium bicarbonate to reduce stinging. Warming the syringe helps. Ice the site beforehand. - **Effectiveness**: Subjectively less dramatic than IV but more practical for sustained protocols. Most patients who try both describe SC as "70-80% of the IV experience." #### Oral NAD+ Precursors (NMN and NR) ##### NMN (Nicotinamide Mononucleotide) - **The Sinclair molecule**: David Sinclair (Harvard) popularized NMN through his research and personal use. He takes 1g NMN daily (per public statements). - **Typical doses**: 250mg-1000mg daily. Most practitioners start at 250-500mg and titrate up. - **Sublingual NMN**: Some formulations designed for sublingual absorption may bypass first-pass metabolism. Evidence for superiority is limited but mechanistically plausible. - **Key study**: Yoshino et al. (2021, Science) — 250mg NMN daily for 10 weeks improved muscle insulin sensitivity in prediabetic postmenopausal women. This is the best human RCT data for NMN. - **Clinical observation**: Most patients notice subtle energy and cognition improvements over 2-4 weeks. Less dramatic than IV but sustainable and affordable. ##### NR (Nicotinamide Riboside) — Niagen/TruNiagen - **More human data than NMN**: Multiple published human trials showing NAD+ elevation and safety. - **Typical doses**: 300-1000mg daily. - **Key studies**: Martens et al. (2018) — 1000mg NR daily for 6 weeks raised NAD+ 60% in healthy middle-aged/older adults. Dollerup et al. (2018) — NR improved body composition in obese men. - **The NR vs NMN debate**: NR has more published human trial data. NMN has the Sinclair endorsement and mechanistic argument (NMN is one step closer to NAD+ in the salvage pathway). In practice, both work. Practitioners should be aware of both options. ##### Niacin (Nicotinic Acid) and Niacinamide - **Old school but relevant**: Niacin raises NAD+ effectively and is dirt cheap. The flushing is the main barrier. - **Niacinamide**: Raises NAD+ without flushing but may inhibit sirtuins at high doses (SIRT1 product inhibition). This is the theoretical downside. - **Some practitioners**: Use low-dose niacin (50-100mg) as part of a comprehensive NAD+ stack. ### The Sinclair vs. Critics Debate (Important Context) - **Sinclair position**: NAD+ decline is a primary driver of aging. NMN supplementation can restore youthful NAD+ levels and activate sirtuins, slowing or reversing aspects of aging. He takes NMN, resveratrol, and metformin personally. - **Critics (Matt Kaeberlein, Charles Brenner, others)**: Argue that Sinclair overstates the evidence. Concerns include: (1) Mouse doses often don't translate to humans, (2) NMN may not cross the cell membrane efficiently in all tissues, (3) The "anti-aging" claims outpace the clinical data, (4) Resveratrol's sirtuin activation is debated, (5) Sinclair's financial conflicts of interest (he co-founded companies selling NAD+ products). - **Brenner position**: As the discoverer of the NR pathway, Brenner argues NR has better pharmacokinetic data than NMN and criticizes the NMN hype. - **Practitioner takeaway**: The basic science (NAD+ declines with age, this matters for health) is solid. The debate is about degree of benefit, optimal delivery, and whether current products deliver on the promise. Do not oversell NAD+ as a fountain of youth, but do recognize it as one of the best-supported longevity interventions. ### Comprehensive NAD+ Protocol (Experienced Practitioners) **Phase 1 — Loading (Weeks 1-2):** - IV NAD+ 500mg x 4 infusions (every 3-4 days), OR - SC NAD+ 200mg daily x 14 days, OR - Oral NMN 500-1000mg daily (less dramatic but accessible) - Methyl support: TMG 500mg 2x/day + methylfolate 1mg + methylcobalamin 5mg **Phase 2 — Maintenance (Ongoing):** - IV NAD+ 500mg monthly, OR - SC NAD+ 100-200mg 2-3x/week, OR - Oral NMN 500mg daily - Continue methyl support at maintenance doses **Phase 3 — Optimization (Stack with):** - Resveratrol 500-1000mg daily (SIRT1 activator — synergistic with NAD+) - Pterostilbene 100-200mg daily (better bioavailable resveratrol analog) - Quercetin 500mg daily (CD38 inhibitor — preserves NAD+ from degradation) - Apigenin 50-100mg daily (another CD38 inhibitor) - Fisetin (senolytic + NAD+ support) - Consider metformin 500-1000mg (Sinclair protocol) — but note metformin may blunt exercise benefits ### Combining NAD+ with Longevity Peptides - **NAD+ + Epitalon**: Addresses two pillars of aging — mitochondrial decline (NAD+) and telomere shortening (Epitalon). Popular longevity clinic combination. - **NAD+ + SS-31**: Double mitochondrial support — NAD+ restores cofactor levels while SS-31 stabilizes cardiolipin and reduces mitochondrial ROS. Synergistic in theory. - **NAD+ + GHK-Cu**: NAD+ for intracellular repair + GHK-Cu for extracellular matrix and gene expression. Complementary anti-aging mechanisms. - **NAD+ + Thymosin Alpha-1**: NAD+ for metabolic rejuvenation + TA1 for immune rejuvenation. Comprehensive aging intervention. - **NAD+ + BPC-157**: Some practitioners use BPC-157 alongside NAD+ for patients with gut issues that may impair oral NAD+ precursor absorption. ### Real Clinical Observations from IV NAD+ Clinics - **Energy**: 85-90% of patients report noticeable energy improvement. Most dramatic in patients with chronic fatigue, long COVID, or significant age-related decline. - **Cognition**: 70-80% report improved mental clarity. Particularly notable in patients 50+. - **Sleep**: 60-70% report improved sleep quality. Some patients report vivid dreams initially. - **Mood**: 50-60% report mood improvement. Some describe it as "emotional resilience" more than euphoria. - **Addiction cravings**: In addiction protocols, 60-70% report significant craving reduction. This is not a cure but a powerful adjunct. - **Exercise performance**: Athletes often report improved recovery and endurance. - **Side effects of IV**: Nausea (30-40%), chest tightness (20-30%), abdominal cramping (15-25%), anxiety during infusion (10-20%). ALL are transient and dose-rate dependent. Slow the drip. - **Non-responders**: 10-15% of patients report minimal subjective benefit. This may relate to individual variation in NAD+ metabolism, CD38 levels, or sirtuin polymorphisms. ### Monitoring - NAD+ blood levels can be measured but are expensive and not standardized across labs - Intracellular NAD+ is what matters, and peripheral blood levels are a rough proxy - Most practitioners rely on clinical response rather than lab monitoring - Monitor homocysteine if concerned about methylation depletion (should stay < 10 μmol/L) - Comprehensive metabolic panel before and during treatment - Consider checking organic acids for methylmalonic acid (B12 status) and FIGLU (folate status) ### Contraindications and Cautions - Active cancer: NAD+ fuels all rapidly dividing cells. Theoretical concern that boosting NAD+ could support tumor growth. This is debated but most practitioners avoid NAD+ in active cancer patients. - Methylation-sensitive patients: Start low, ensure methyl support - Bipolar disorder: High-dose NAD+ (especially IV) can trigger manic episodes in susceptible individuals - Pregnancy/lactation: Insufficient safety data - Gout: Niacin pathway can raise uric acid

Dosing Protocols

Contraindications & Cautions

• hard stop — Pregnancy
  No adequate human safety data for IV NAD+ during pregnancy. Altering cellular redox balance and sirtuin activity during fetal development poses theoretical risk.
  Action: Do not use IV NAD+ during pregnancy.
• hard stop — Breastfeeding
  No data on effects of supraphysiologic NAD+ on breast milk composition or nursing infant. Safety not established.
  Action: Do not use IV NAD+ while breastfeeding.
• hard stop — Under 18 years of age
  Peptide protocols are not designed for pediatric use.
  Action: Do not provide to individuals under 18.
• caution — Active cancer
  NAD+ is required for PARP-mediated DNA repair in all cells including tumor cells. Supraphysiologic NAD+ may support tumor cell survival and resistance to DNA-damaging therapies. Some cancers upregulate NAD+ salvage pathways.
  Action: Avoid in patients with active cancer, especially those on DNA-damaging chemotherapy or PARP inhibitors. Consult oncologist.
• requires physician — PARP inhibitors (olaparib, niraparib, etc.)
  PARP inhibitors work by depleting NAD+ and preventing DNA repair in tumor cells. Exogenous NAD+ administration may directly antagonize PARP inhibitor efficacy and reduce anticancer activity.
  Action: Do not use concurrently with PARP inhibitor therapy. Discuss with oncologist.
• caution — Gout or hyperuricemia
  NAD+ metabolism generates nicotinamide, which is metabolized to N-methylnicotinamide and subsequently may increase uric acid production. High-dose IV NAD+ may exacerbate gout.
  Action: Monitor uric acid levels. Use with caution in patients with gout history. Ensure adequate hydration.

Stacks featuring this peptide

Research Summary

## NAD+ — Research Summary (Comprehensive) ### Tier 1 (Strong Clinical Evidence) - **Fundamental biochemistry**: NAD+ as essential coenzyme in cellular metabolism is textbook biochemistry. Not debated. - **Age-related NAD+ decline**: Multiple studies confirm 50%+ decline in NAD+ levels between ages 40-60 across tissues. Camacho-Pereira et al. (2016, Cell Metabolism) identified CD38 as a primary driver. - **NMN insulin sensitivity**: Yoshino et al. (2021, Science) — 250mg NMN daily for 10 weeks improved muscle insulin sensitivity in prediabetic postmenopausal women. This is the landmark NMN human RCT. - **NR raises NAD+ in humans**: Martens et al. (2018, Nature Communications) — 1000mg NR/day for 6 weeks raised blood NAD+ 60% and showed trends toward reduced blood pressure and arterial stiffness in healthy older adults. - **NAD+ and sirtuin biology**: The NAD+-sirtuin axis is well established in molecular biology. Hundreds of published studies confirm NAD+-dependent sirtuin activity regulates DNA repair, metabolism, inflammation, and stress resistance. - **PARP-NAD+ competition**: Established that DNA damage increases PARP activity, depleting NAD+ and creating a vicious cycle of genomic instability. Multiple labs have replicated this. ### Tier 2 (Moderate Evidence — Published Studies, Animal Data, Small Human Trials) - **NMN cardiovascular**: Preclinical data shows NMN improves cardiac function, vascular elasticity, and capillary density in aged mice. Human cardiovascular trials are underway. - **NR body composition**: Dollerup et al. (2018, American Journal of Clinical Nutrition) — NR improved body composition in obese men. Effects were modest but statistically significant. - **NAD+ and neurodegeneration**: Multiple preclinical studies show NAD+ restoration slows neurodegeneration in Alzheimer, Parkinson, and ALS models. Human translation is limited but promising. - **NMN exercise capacity**: Yi et al. (2023) — NMN supplementation improved aerobic capacity in recreational runners. Small study but notable. - **Oocyte quality**: Bertoldo et al. (2020, Cell Reports) — NMN restored oocyte quality and fertility in aged mice. Significant interest for reproductive medicine. - **CD38 as therapeutic target**: Blocking CD38 (with quercetin, apigenin, or specific inhibitors) preserves NAD+ levels. This approach may complement direct NAD+ supplementation. - **Methylation depletion**: Biochemically established that nicotinamide metabolism consumes methyl groups via NNMT. Clinical significance confirmed by practitioner observations of worsened methylation symptoms. ### Tier 3 (Emerging/Anecdotal — Clinical Observation, Case Series) - **IV NAD+ for addiction**: The BR+NAD protocol has been used in specialty clinics for 15+ years. Published case series and clinical observations report significant benefit for alcohol, opioid, and stimulant withdrawal and craving reduction. No placebo-controlled RCTs exist. - **IV NAD+ for chronic fatigue**: Clinicians report dramatic improvements in energy and function for chronic fatigue and long COVID patients. Anecdotal but consistent across multiple clinics. - **Subjective anti-aging effects**: Patients consistently report improved energy, cognition, sleep, and mood with sustained NAD+ protocols. While subjective, the consistency across thousands of patients at multiple clinics is notable. - **NAD+ for neuropsychiatric conditions**: Some clinicians use IV NAD+ for depression, anxiety, PTSD, and traumatic brain injury. Results are promising but uncontrolled. - **Long-term safety**: No significant long-term adverse effects reported across thousands of patient-months. The safety profile appears excellent, with the caveat that very-long-term data (10+ years) does not yet exist. - **SC NAD+ protocols**: Growing practitioner experience with subcutaneous NAD+ as a more practical alternative to IV. Absorption and efficacy data is limited but clinical experience is accumulating rapidly. ### Key Research Gaps - **No large, long-term RCTs**: The biggest limitation. Most human studies are small (N<100) and short (< 6 months). - **IV NAD+ needs RCTs**: Despite 15+ years of clinical use, there are no placebo-controlled IV NAD+ trials. The clinical observations are compelling but need validation. - **Optimal dose and route**: The ideal balance of cost, efficacy, and practicality across IV, SC, and oral routes is not established. - **Cancer safety**: Theoretical concern about NAD+ and cancer needs prospective evaluation. - **Biomarkers**: Better biomarkers for intracellular NAD+ status and response prediction are needed. - **The Sinclair debate resolution**: Whether NMN supplementation in humans produces the dramatic lifespan/healthspan benefits seen in mice remains unresolved. ### Bottom Line NAD+ is one of the most scientifically grounded longevity interventions available. The basic science is robust, the clinical observations are remarkably consistent, and the safety profile is excellent. The gap between the strength of the biological rationale and the current state of clinical trial data is the main limitation. Practitioners who offer NAD+ are on solid scientific footing, even if the field has not yet caught up with the full clinical evidence standard.